Influence of antidrug antibodies on plectasin efficacy and pharmacokinetics.
Plectasin is a 4.4-kDa antimicrobial peptide with the potential to be a treatment of infections caused by gram-positive bacteria. Since plectasin is a large molecule compared to conventional antibiotics, the development of antidrug antibodies (ADAs) could be anticipated. The immunogenic properties of plectasin were assessed through immunization studies. In mice treated for 5 days with one to two daily subcutaneous doses of plectasin, no antibody response was observed. If the animals were immunized again, after a rest period, low levels of antibodies developed in approximately half the animals. Additionally, mice were immunized with plectasin in Freund's incomplete adjuvant (FIA). Ninety-two percent of these mice developed ADAs after repeated immunizations, with two-thirds having high levels of antibodies. An agar diffusion bioassay showed that sera from animals immunized with plectasin did not inhibit the efficacy of the drug, while hyperimmune sera from animals in which an immune response was provoked by immunization with plectasin in FIA reduced the efficacy of plectasin at the lowest concentration tested. Studies in the murine peritonitis model showed an excellent efficacy of plectasin for the treatment of Streptococcus pneumoniae infections both in naïve animals and in animals with ADAs. No difference in bacterial counts was seen when the animals were treated with plectasin at 2.5 mg/kg of body weight, a dose below the expected therapeutic level. When animals were treated with plectasin at 0.625 mg/kg, the effect was reduced but not neutralized in animals with high levels of ADAs. No animals showed signs of hypersensitivity or injection site reactions toward plectasin, and the half-life of the compound did not vary between animals with and without antibodies.
Brinch
Karoline Sidelmann
KS
Novozymes A/S, Anti-Infective Discovery, Building 1A1.13, Krogshøjvej 36, Bagsvaerd DK-2880, Denmark. kbri@novozymes.com
Frimodt-Møller
Niels
N
Høiby
Niels
N
Kristensen
Hans-Henrik
HH
D000818:Animals; D000906:Antibodies / Q000097:blood / Q000502:physiology*; D005260:Female; D006207:Half-Life; D007114:Immunization; D051379:Mice; D010455:Peptides / Q000276:immunology / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010538:Peritonitis / Q000188:drug therapy; D011008:Pneumococcal Infections / Q000188:drug therapy*
D000906:Antibodies; D010455:Peptides; C504857:plectasin
J Antimicrob Chemother. 2003 Dec;52(6):967-73
14613958
Curr Opin Pharmacol. 2006 Oct;6(5):468-72
16890021
Dev Biol (Basel). 2002;109:59-69
12434914
Clin Ther. 2002 Nov;24(11):1720-40; discussion 1719
12501870
Nat Biotechnol. 2007 May;25(5):555-61
17483842
J Antimicrob Chemother. 1993 May;31 Suppl D:55-60
8335524
Neurology. 2007 Oct 2;69(14):1386-7
17909150
J Neuroimmunol. 2005 Sep;166(1-2):180-8
16005084
Curr Eye Res. 2005 Jul;30(7):505-15
16020284
Neurology. 2003 Nov 11;61(9 Suppl 5):S11-2
14610103
Antimicrob Agents Chemother. 1995 Jun;39(6):1253-8
7574511
N Engl J Med. 2007 Mar 1;356(9):904-10
17329697
J Immunol Methods. 2004 Jun;289(1-2):1-16
15251407
Antimicrob Agents Chemother. 1998 Jun;42(6):1355-60
9624475
J Investig Allergol Clin Immunol. 2009;19(2):80-90
19476012
Toxicology. 2001 Feb 2;158(1-2):71-4
11164995
Curr Opin Mol Ther. 2004 Feb;6(1):10-6
15011776
Invest Ophthalmol Vis Sci. 2002 Dec;43(12):3712-6
12454041
Clin Pharmacol Ther. 2008 Nov;84(5):624-7
18701885
Diagn Microbiol Infect Dis. 2006 Sep;56(1):69-74
16546341
Blood. 1990 Jan 15;75(2):518-23
2295006
Curr Pharm Biotechnol. 2002 Dec;3(4):349-60
12463417
Nature. 2005 Oct 13;437(7061):975-80
16222292
Trends Biotechnol. 2006 Jun;24(6):274-80
16631266
J Pharm Biomed Anal. 2005 Sep 15;39(3-4):364-75
15963677
Nat Biotechnol. 2006 Dec;24(12):1551-7
17160061
JAMA. 2007 Oct 17;298(15):1763-71
17940231
Med Clin North Am. 2006 Jan;90(1):233-60
16310532
Neurology. 1998 May;50(5):1266-72
9595973